Market Closed - Euronext Paris 11:35:10 2024-07-19 am EDT 5-day change 1st Jan Change
1.226 EUR -7.96% Intraday chart for VALBIOTIS -13.30% -75.48%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Valbiotis Terminates Licensing, Supply Deal With Nestlé Unit MT
Valbiotis: share price plummets, Nestlé agreement terminated CF
Valbiotis SA Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Valbiotis: launch of Valbiotis PRO Cholesterol in May CF
Valbiotis: capital increase successfully completed CF
Valbiotis: 15 ME capital increase CF
Valbiotis' Plant Extract Receives New Dietary Ingredient Status from US FDA MT
Valbiotis SA Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Valbiotis: share price rises on success of clinical study CF
Valbiotis SA Presents the Full Results of the Phase II/III REVERSE-IT Study: Impressive Efficacy of TOTUM 63 Against Prediabetes and the Early Stages of Type 2 Diabetes, a First for a Non-drug Active Substance CI
VALBIOTIS : Invest Securities confirms its recommendation CF
Global markets live: BP, Walt Disney, Amazon, PepsiCo, Delta Airlines.... Our Logo
Valbiotis: share price up, broker in support CF
VALBIOTIS : Oddo BHF raises its target price CF
Valbiotis: share price soars, broker adjusts target CF
VALBIOTIS : promising study, Invest Sec. raises its target CF
Valbiotis: 'major' breakthrough in type 2 diabetes CF
Valbiotis Announces the Large Success of the REVERSE-IT International Multicentric Phase II/III Clinical Study on TOTUM-63 CI
Global markets live: Deliveroo, Adobe, Berkshire Hathaway, First republic Bank, Robinhood Markets... Our Logo
Valbiotis SA Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Valbiotis SA Announces the Last Visit of the Last Patient in the Phase II/III REVERSE-IT Study on TOTUM•63, in Partnership with Nestlé Health Science CI
Global markets live: GM, Pfizer, Exxon, UBS, Boeing... Our Logo
Valbiotis: encouraging results in hypertension CF
Valbiotis Announces Positive Results in the Bioavailability and Mode of Action TOTUM--854 Clinical Study, Against High Blood Pressure CI
Valbiotis SA Announces the Signature of a Research Partnership in Intestinal Microbiota With the MEDIS Unit From the Clermont Auvergne University CI
More charts
VALBIOTIS is a French Research & Development company committed to scientific innovation for the prevention and control of metabolic diseases. VALBIOTIS specializes in the development of innovative nutritional solutions for cardio-metabolic disease prevention and nutritional support for patients. The products are intended for food and pharmaceutical industries. VALBIOTIS is essentially intervening in the prevention of type 2 diabetes, NASH (non-alcoholic steatohepatitis), obesity and cardiovascular diseases. VALBIOTIS has established numerous partnerships with academic centers of excellence in France and overseas, including the University of La Rochelle, the CNRS, and the Clermont Auvergne University in Clermont-Ferrand where the company has opened a secondary school. With these agreements, since its inception VALBIOTIS has benefited from a strong leverage thanks notably to experts and technical partners involved in its projects.
More about the company
Mean consensus
Number of Analysts
Last Close Price
1.226 EUR
Average target price
5.1 EUR
Spread / Average Target

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. ALVAL Stock
  5. Valbiotis Terminates Licensing, Supply Deal With Nestlé Unit